Repare <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initial Data from Phase 1 LIONS Trial of First-in-Class PLK4 Inhibitor RP-1664 in Advanced Solid Tumors
Repare Therapeutics Inc. has announced that it will present initial topline safety, tolerability, and early efficacy data from its Phase 1 LIONS clinical trial at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The LIONS trial (NCT06232408) is a first-in-human, multicenter, open-label Phase 1 study evaluating RP-1664, a potential first-in-class, highly selective oral PLK4 inhibitor, as monotherapy in adult and adolescent patients with TRIM37-high solid tumors. The data will be shared in a poster presentation on October 25, 2025, and a copy of the poster will be available on the Repare Therapeutics website at the start of the session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013080571) on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.